HKTDC launches International Healthcare Week

Asia Summit on Global Health features Nobel laureate Prof Roger Kornberg speaking on cutting-edge biotech advances.
Hong Kong International Medical and Healthcare Fair attracts some 300 exhibitors and diverse country and regional pavilions from around the world.

HONG KONG, May 7, 2024 – (ACN Newswire) – The third International Healthcare Week (IHW), organised by the Hong Kong Trade Development Council (HKTDC), takes place from 15 to 31 May. The week’s flagship event, the Asia Summit on Global Health (ASGH), co-organised by the Hong Kong SAR Government (HKSAR) and HKTDC, will be held at the Hong Kong Convention and Exhibition Centre (HKCEC) on 16 and 17 May. Another flagship event, the Hong Kong International Medical and Healthcare Fair (Medical Fair), will run concurrently from 16 to 18 May, highlighting Hong Kong’s strengths in healthcare.

Margaret Fong, Executive Director of the HKTDC, said: “Hong Kong’s healthcare system is world-renowned. The 2023 Policy Address announced various measures to turn Hong Kong into a health innovation hub and develop its silver economy. We have been keen to promote medical technology and devices, and this year, the concurrent ASGH and Medical Fair once again bring together local and international healthcare experts to discuss the industry’s hot topics, including AI, healthy ageing and Chinese medicine. A Nobel laureate in Chemistry will also highlight the latest innovative biotech solutions. The two events will showcase a series of robotics technologies as well as the latest healthcare products and solutions for the silver economy. They offer exhibitors, investors and buyers a platform to build connections and foster cross-sector collaboration. This will play an important role in transforming Hong Kong into a health and medical innovation hub.”

Aside from ASGH and the Medical Fair, IHW features the Hospital Authority Convention, among many other industry events.

Industry leaders explore healthcare opportunities

Themed Innovation . Inclusion . Impact, the fourth ASGH brings together medical and healthcare government representatives and organisations, internationally renowned scientists and medical experts, investors and business leaders from around the world. In addition to public health, medtech, international trade cooperation and investment, they will analyse the industry’s outlook and business opportunities.

Dr Peter K N Lam, Chairman of the HKTDC, presents welcome remarks, John Lee, Chief Executive of the HKSAR, delivers opening remarks and Prof Cao Xuetao, Vice-Minister of the National Health Commission of the People’s Republic of China, gives special remarks on the opening day of ASGH.

The ASGH Plenary Sessions explore opportunities in the healthcare industry and promote cooperation across the medical and healthcare fields. For the first plenary, Prof Lo Chung-mau, Secretary for Health of the HKSAR, shares his vision and addresses the preparatory work for the establishment of the Hong Kong Centre for Medical Products Regulation and the progress made in promoting Hong Kong as a health innovation hub.

Other speakers include Prof Lau Chak-sing, Dean of Medicine of The University of Hong Kong; Prof Lo Yuk Lam, President of the HK Bio-Med Innotech Association; Dr Sun Zhigang, Senior Vice President of Luye Pharma Group Ltd, and more. They will discuss the drug approval systems in Mainland China and overseas, exploring how they can benefit the healthcare ecosystem.

At the second plenary, Prof Roger Kornberg, Nobel Laureate in Chemistry in 2006 highlights biotech advances and engages in dialogue on emerging technologies and healthcare innovation trends with Victor L L Chu, Chairman and CEO of First Eastern Investment Group, and Leslie Lu, Executive Director and CEO of EC Healthcare, among others.

During the Dialogue with Global Pioneer in Health session, Prof Michael Hanna, Director of UCL Queen Square Institute of Neurology, sheds light on the latest trends and findings in neurology. ASGH also spotlights China’s healthcare ecosystem, highlighting the latest developments in healthcare in the vast market, key investment areas and major trends shaping the country’s healthcare sector.

For the plenary session on the second day of the Summit, The Hon Bernard Charnwut Chan, Chairman and President of Asia Financial Holdings Limited; Dr Sangtae Kim, Chief Technology Officer of Bertis Bioscience; Yasushi Okada, Representative Corporate Officer and COO of Eisai Co., Ltd.; Dr Sarah Salvilla, Group Chief Health Officer of FWD Group, and more will explore the current landscape of medical innovation in Asia, encompassing trends, investments and collaboration.

Thematic sessions discuss precision medicine, innovative drugs, neuroscience, healthcare investment prospects, opportunities in healthcare insurance and more.

InnoHealth Showcase and deal-making connect start-ups with investors

ASGH deal-making connects investors and project owners from across the globe in-person and online to discuss collaboration opportunities.

Participating investors represent a diverse range of backgrounds, including angel investors, venture capitalists and corporate venture capital, private equity firms, family offices and more. Investment interests span pharmaceuticals, medical devices and diagnostics, AI and digital health, and community health and wellness.

The exhibition area, which includes the InnoHealth Showcase, features healthcare investment projects and cutting-edge technologies from over 150 companies at the forefront of healthcare innovation. Among them, over 70 healthcare start-ups and projects, many of which are award-winning, are led by six local universities and Cyberport. Besides the Innovation and Technology Commission, Investment NSW and the Sichuan Provincial Administration of Traditional Chinese Medicine bring healthcare start-ups and institutions to Hong Kong for the first time to help them connect with potential partners and investors.

Medical Fair facilitates industry collaboration

The Medical Fair, organised by the HKTDC and co-organised by the Hong Kong Medical and Healthcare Device Industries Association (HKMHDIA), serves as the ideal platform for industry professionals, including R&D institutions, manufacturers, public healthcare institutions, hospitals, clinics, wholesalers and medical healthcare professionals, from around the world to establish business connections and gather insights on the latest developments in the medical field.

Themed Innovations Boosting Smart Health Experience, this year’s Medical Fair welcomes some 300 exhibitors from eight countries and regions and features a wide range of exhibition zones, including Biotechnology, Hospital Equipment, Rehabilitation and Elderly Care Products, Startup, and the HKMHDIA Pavilion zones.

Exhibitors showcase medical technology solutions that utilise AI and robotics technology. In the Laboratory Equipment and Manufacturing Solutions zone, exhibitors feature cold-chain logistics solutions that incorporate innovative, efficient data recording devices. These solutions enable real-time monitoring of vaccine and medicine delivery status, ensuring compliance with regulatory requirements, while optimising cost control.

The Medical Fair features a strong line-up of leading research and academic institutions, including six local universities. The Hong Kong Science and Technology Parks Corporation (HKSTP) pavilion showcases the latest advancements in medical equipment, testing and analysis solutions and telemedicine technologies of over 30 companies. Additionally, with the support of the HKMHDIA, 20 companies exhibit their latest medical imaging equipment and health monitoring products.

The debut Hungary, Chongqing (China) and Jilin (China) pavilions, alongside the returning Canada pavilion, showcase a range of medical instruments, reagent consumables, diagnostic technologies and antibacterial coatings applicable to various fields, such as analytical testing science, clinical diagnosis, food and pharmaceutical safety and life sciences. Traditional Chinese medicine and supplements are also featured.

One of the many Medical Fair events, the HKMHDIA Medical Fair Forum discusses Hong Kong’s smart healthcare innovation and transformation. Other seminars explore the latest trends in smart ageing technology, IoT applications in digital healthcare, the application of mixed reality and AI for medical imaging, and more.

Using the HKTDC EXHIBITION+ hybrid model, the physical fair from 16 to 18 May is complemented by the Click2Match smart business matching platform, via which buyers can extend their sourcing journey from 9 to 25 May.

Asia Summit on Global Health
Date	16-17 May 2024 (Thursday to Friday)
Time	The Opening Session will begin at 10:00 am
Venue	Hong Kong Convention and Exhibition Centre (HKCEC) Hall 3FG
Hong Kong International Medical and Healthcare Fair
Date	16-18 May 2024 (Thursday to Saturday)
Venue	Hong Kong Convention and Exhibition Centre (HKCEC) Hall 3DE

Photo download: https://bit.ly/4b8utEm

Prof Roger Kornberg, 2006 Nobel laureate in Chemistry is one of the featured keynote speakers at the Asia Summit on Global Health.

Prof Michael Hanna, Director of UCL Queen Square Institute of Neurology, shares the latest trends and findings in neurology in the Dialogue with Global Pioneer in Health session at the Asia Summit on Global Health.

ASGH deal-making facilitates connections between project owners and investors in-person and online.

The HKSTP pavilion showcases medical testing and analysis technologies at the Hong Kong International Medical and Healthcare Fair.

With the support of the HKMHDIA, 20 companies exhibit the latest medical imaging equipment and health monitoring products.

This year’s Medical Fair features eight key product zones, including Biotechnology, Hospital Equipment and Rehabilitation and Elderly Care.

The Asia Summit on Global Health was held successfully last year.

The Medical Fair attracts global buyers seeking the latest advances in medical equipment, technological solutions and healthcare products.

Websites

International Healthcare Week: https://internationalhealthcareweek.hktdc.com/en

Asia Summit On Global Health: https://www.asiasummitglobalhealth.com/conference/asgh/en
Programme: https://www.asiasummitglobalhealth.com/conference/asgh/en/programme
Speakers: https://www.asiasummitglobalhealth.com/conference/asgh/en/speaker

Hong Kong International Medical and Healthcare Fair: https://www.hktdc.com/event/hkmedicalfair/en
List of products: https://www.hktdc.com/event/hkmedicalfair/en/product
Activity schedule: https://www.hktdc.com/event/hkmedicalfair/en/intelligence-hub

Members of the media interested in interviewing ASGH speakers can send an email to hktdc@hkstrategies.com on or before 10 May, 2024.

Media enquiries

For enquiries, please contact Hill & Knowlton:

Joyce Kwong	Tel: (852) 2894 6321	Email: joyce.kwong@hillandknowlton.com
Lynn Zhang	Tel: (852) 2894 6321	Email: lynn.zhang@hillandknowlton.com

HKTDC’s Communications & Public Affairs Department:

Asia Summit on Global Health

Clayton Lau

Tel: (852) 2584 4472

Email:clayton.y.lauw@hktdc.org

Hong Kong International Medical and Healthcare Fair

Jane Cheung

Tel: (852) 2584 4137

Email:jane.mh.cheung@hktdc.org

Media Room: http://mediaroom.hktdc.com

About HKTDC

The Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong’s trade. With 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Follow us on Twitter @hktdc and LinkedIn

JBM Healthcare Issues Positive Profit Alert

HONG KONG, May 5, 2024 – (ACN Newswire) – JBM (Healthcare) Limited (“JBM Healthcare” or the “Company”; Stock Code: 2161, together with its subsidiaries, the “Group”), a leading branded healthcare products marketer and distributor in Hong Kong, has announced a positive profit alert. Based on a preliminary review of the unaudited consolidated management accounts of the Group for the financial year ended 31 March 2024 and the information currently available to the board of directors of the Company, the Group is expected to record an increase in the consolidated profit attributable to shareholders for the year ended 31 March 2024 (“Consolidated Profit”) by not less than 120% as compared to that for the same period last year.

The significant increase in Consolidated Profit stems from a combined effect of the improvement in overall retail market sentiment due to the gradual recovery of tourist travel to Hong Kong, alongside the effective execution of advertising and marketing strategies for our key brands under the proprietary medicine category, notably Po Chai Pills and Ho Chai Kung. This promising performance underscores our disciplined execution of growth strategies along the offline and online platforms, with positive progress being made on the cross-border e-commerce trade.

JBM Healthcare has a diversified portfolio spanning branded medicines, proprietary Chinese medicines, and health and wellness products. The Group continues to make progress on its strategic priorities, including expanding e-commerce platforms locally and cross-border, exploring opportunities in traditional Chinese medicines for Hong Kong and the Greater Bay Area, adapting its product mix to consumer trends, and enhancing commercial execution.

For details, please refer to the announcement on HKEX.

About JBM (Healthcare) Limited (Stock Code: 2161)

JBM Healthcare is a Hong Kong-based company that markets and distributes branded healthcare products across Greater China, Southeast Asia, and certain other countries. The Group is a unique field player with marketing expertise and a drug heritage that prioritises product efficacy and quality to meet consumers’ healthcare needs. As a renowned healthcare brand operator in Hong Kong, the Group carries a wide-ranging portfolio of branded healthcare products comprising branded medicines, proprietary Chinese medicines, and health and wellness products, which include well-recognised household brands such as Po Chai Pills, Ho Chai Kung Tji Thung San, Contractubex, BITE-X, Mederma for Kids, Tong Tai Chung Woodlok Oil, Flying Eagle Woodlok Oil, Saplingtan, Shiling Oil and Konsodona Medicated Oil. JBM Healthcare has been a constituent stock of the MSCI Hong Kong Micro Cap Index since 27 May 2021. For more details about JBM Healthcare, please visit: www.jbmhealthcare.com.hk

Elevate Your Sleep Game This World Health Day with LAC

SINGAPORE, Apr 25, 2024 – (ACN Newswire) – Despite the well-known importance of sleep for physical and mental well-being, a significant portion of Singaporeans find themselves grappling with chronic sleep deprivation. According to a recent study published by YouGovsg, Singaporeans have been deemed to be the most sleep-deprived globally. Only 1 in 4 Singaporeans have an ideal sleep cycle of 7 hours or more, with insomnia being a highly common sleep disorder that affects up to 15.3% of the local population. This phenomenon has far-reaching implications for individual health, productivity, and overall societal well-being.

LAC understands the importance of the role that sleep plays in our day to day overall wellbeing. In conjunction with World Health Day, LAC is looking to raise awareness among Singaporeans from all walks of life who are struggling with having healthy sleep habits, highlighting the importance of having adequate sleep and how it enhances their overall well-being.

LAC’s TriAction Sleep Formula, formulated with a blend of ingredients such as Valerian Root, Saffron Extract, Magnesium and Melatonin helps to regulate sleep cycle and supports relaxation throughout the entire duration. Unlike conventional sleep aids that offer temporary respite but risk fostering dependency, LAC’s TriAction Sleep Formula harnesses the power of a proprietary blend of ingredients and herbs, offering a non-habit forming solution for those grappling with sleep disturbances. Engineered with triple-layer technology, it ensures both immediate and sustained release, fostering not only relaxation but also an elevated sleep experience.

Insufficient sleep also poses a significant risk of fat accumulation in the liver, a fact often overlooked. Enter LAC’s Liver Protector, meticulously crafted with ingredients drawn from traditional Chinese medicine such as Sanchi and Red Peony Root. The potent elements found in LAC’s Liver Protector aid in detoxifying the body, combating lipid build up and restoring hormonal imbalance, reducing the risk of liver disease that is often associated with poor or inadequate sleep.

OrbusNeich’s Joint Venture Kicks Off TricValve Clinical Trial in Mainland China

HONG KONG, Apr 24, 2024 – (ACN Newswire) – OrbusNeich Medical Group Holdings Limited (“OrbusNeich” or the “Group”; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures, announced today that the Group’s joint venture OrbusNeich P+F Company Limited (“ON P&F”) has commenced the clinical trial for the TricValve Transcatheter Bicaval Valve System (“TricValve”), to treat patients with hemodynamically relevant tricuspid insufficiency and caval reflux, on April 22, 2024 across Mainland China.

The CE-marked medical device was named a Breakthrough Device and an Innovative Medical Device by the FDA in the United States and NMPA in China, respectively. It has effectively treated a 56-year-old patient with severe tricuspid regurgitation, marking the commencement of the clinical trial across Mainland China.

Led by principal investigator Prof. Ge Junbo, Academician Zhongshan Hospital, Fudan University, and his team, the clinical trial aims to assess the safety and efficacy of TricValve. Prof. Ge Junbo had himself performed the implantation procedure on a patient. A team of experts of Zhongshan Hospital, one of the 13 medical institutions participating in the trial, believed the groundbreaking therapy could potentially revolutionize treatment options for patients, offering them new hope and improved outcomes.

Mr. Peter Peh, General Manager of OrbusNeich P&F, said, “We are pleased to see TricValve moving into clinical trial, marking the first successful implantation of a percutaneous transcatheter bicaval device in a patient by cardiologists in Mainland China, to address severe tricuspid valve regurgitation. Before that, patients with this valvular heart disease are typically deemed unfit for open-heart surgery. They had limited treatment options, and had to endure severe symptoms and a shortened lifespan. With the advent of TricValve, patients can look forward to having better quality of life and live longer. It is our privilege to offer this life-changing therapy to patients. As our first patient has been doing exceptionally well after the procedure, we hope to extend relevant care to more patients in the future.”

Via ON P&F, the Group has ventured into the structural heart domain. In addition to TricValve, ON P&F also has a comprehensive pipeline of structural heart interventional devices, including Vienna Aortic Valve, a transcatheter aortic valve replacement (TAVR) product; Vienna Mitral Valve — Replacement, a transcatheter mitral valve replacement (TMVR) product; Vienna Pulmonary Valve — Replacement, a transcatheter pulmonary valve replacement (TPVR) product, and balloon expandable valves, which are complementary additions to the Group’s series of self-expandable heart valve devices. The strategic move has opened doors for the Group to new opportunities in the transcatheter valve replacement and repair market recording double-digit growth in recent years. The notable shift from traditional open-heart surgery to minimally invasive transcatheter therapies will present the Group with substantial growth potential in the medium and long term.

About TricValve

TricValve, a transcatheter bicaval valve system, is comprised of two self-expanding biological valves used to treat patients with hemodynamically relevant tricuspid insufficiency and caval reflux. The prostheses are implanted percutaneously into the superior and inferior vena cava without disturbing the native tricuspid valve. It is especially intended for use for patients at extreme risk or who are inoperable for open surgical therapy.

TricValve obtained the CE Mark in 2021, received Breakthrough Device Designation from the FDA in 2020, and was granted an Innovative Medical Device designation by the NMPA in 2022.

About OrbusNeich Medical Group Holdings Limited

OrbusNeich is a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Headquartered in Hong Kong, China, OrbusNeich sells its products in more than 70 countries and regions worldwide. It is also actively expanding into neuro vascular intervention and structural heart disease. As at December 31, 2023, OrbusNeich has more than 240 granted patents and published patent applications worldwide. Its in-house R&D team has more than two decades of product development experience and has developed world-leading proprietary technologies.

For more information, please visit the Group’s official website: https://orbusneich.com/

Dogs Thrive on Vegan Diets, Demonstrates the Most Comprehensive Study So Far

WINCHESTER, ENGLAND, Apr 24, 2024 – (ACN Newswire) – The longest, most comprehensive peer-reviewed study so far has demonstrated that dogs fed nutritionally-sound vegan diets maintain health outcomes as well as dogs fed meat. The study, published in leading scientific journal PLOS ONE, comprehensively assessed the health of 15 dogs by analysing blood cells and biochemistry, blood nutrient levels, urine, veterinary clinical parameters, and monthly pet owner questionnaires. The dogs were fed solely vegan diets based on pea protein for an entire year – just under one tenth of an average dog lifespan, or around seven human years.

Dr. Linde with ‘Rylee’

Overweight or obese dogs lost weight, whilst the remainder maintained normal weight. No clinically significant changes occurred within blood and urine. Blood levels of amino acids and vitamins were all generally maintained.

In a few cases, previous deficiencies following a meat-based diet either improved or disappeared, including L-taurine and L-carnitine (important for cardiac health), vitamin D (indispensable for immunity and bone health), and folate (required to produce red blood cells).

The study was particularly interesting, given recent suggestions that peas might contribute to heart disease in dogs in the US. Although no credible evidence has been found, such concerns have persisted in some quarters. In the current study, dogs were fed pea-based vegan pet food, for one year. Blood markers of cardiac health were assessed, with no signs of heart disease found. Indeed, in some cases indicators of cardiac health improved.

Stated lead researcher, veterinarian Dr. Annika Linde from the Western University of Health Sciences near Los Angeles says, “Evolutionary adaptations have resulted in a digestive system that enables dogs to maintain health on nutritionally complete omnivorous diets, including those free of animal ingredients. Our study offers new evidence on outcomes in clinically healthy dogs who thrive without consumption of animal-derived ingredients. Notably, foods produced independent of factory farming are also more sustainable and ethical.”

Study co-author Dr. Melgarejo highlighted the potential environmental benefits of such diets, “If dogs and cats in the U.S. were their own nation, they would rank fifth in global meat consumption, surpassed only by Russia, Brazil, USA, and China, according to the UCLA Institute of the Environment and Sustainability.”

Veterinary Professor Andrew Knight has published several of the key studies in this field, including very large-scale studies showing that both dogs and cats normally achieve equivalent or superior health outcomes, when fed nutritionally-sound vegan diets. He also analysed the environmental benefits of vegan pet diets in a major recent study. He stated that “If all the world’s dogs went vegan, it would save more greenhouse gases than those emitted by the UK, land larger than Mexico, and 450 million additional people could be fed with food energy savings – more than the entire EU population. With 13 studies now demonstrating good health outcomes achieved by nutritionally-sound vegan pet diets, and several others demonstrating major environmental benefits, a compelling case now exists for environmentally-friendly vegan pet diets.”

Contact Information:
Andrew Knight
Veterinary Professor of Animal Welfare
andrew.knight@winchester.ac.uk

SOURCE: Representing Animals Foundation

View the original press release on newswire.com.

China Medical System: New Drug Application of Desidustat Tablets Accepted in China

Desidustat Tablets are novel, oral HIF-PHI for treating anaemia in non-dialysis adult chronic kidney disease patients. The Product is administrated orally, thus expecting to improve the treatment compliance of patients and to meet the unmet treatment needs in the field of CKD anaemia, including both dialysis and non-dialysis patients.
China Phase III trial of the Product has demonstrated positive results. The primary endpoint has indicated that Desidustat is more effective than placebo in increasing Hb level.
Currently, 4 innovative drugs of CMS have entered into commercialization stage. Meanwhile, continuous advance of products’ clinical development and registration process such as Desidustat Tablets is expected to enrich the Group’s marketed innovative product portfolio, and generate new driving force to the Group’s sustainable and healthy development.

SHENZHEN, CHINA, Apr 23, 2024 – (ACN Newswire) – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 22 April 2024, the New Drug Application (NDA) of Desidustat Tablets (“Desidustat Tablets” or the “Product”) has been accepted by the National Medical Products Administration of China (NMPA). The Product is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in non-dialysis adult, Chronic Kidney Disease (CKD) patients.

CKD involves the gradual loss of functioning of kidneys and eventually leads to kidney failure. If kidneys are healthy, they will naturally secrete beneficial levels of a hormone called Erythropoietin (EPO), which encourages red blood cell production. If the kidneys are impaired, they will produce reduced levels or tire of EPO production completely, leading to anaemia. HIF-PHI promotes erythropoiesis through increasing endogenous erythropoietin, improving iron availability and reducing hepcidin.

It is estimated that more than 120 million people are living with CKD in China[1]. Anaemia is one of the frequent complications of CKD. A survey in China showed that the prevalence of anaemia in patients at CKD stage 1 to 5 were 22.0%, 37.0%, 45.4%, 85.1%, and 98.2%, respectively[2]. The target-achieving rate (the haemoglobin (Hb) level reaching the target value (110~120g / L)) was only 8.2% for anaemia patients in non-dialysis CKD and 35.2% for haemodialysis CKD, showing a large unmet healthcare need[3].

China Phase III trial of the Product has demonstrated positive results. The primary endpoint of the Hb mean change from baseline to the period of Week 7-9 has indicated that, Desidustat is more effective than placebo in increasing Hb level. The least squares mean and 95% CI of Hb change from baseline to the period of Week 7-9, using covariance model analysis, has shown an increase of 16.38 g/l [95%CI: 14.50, 18.26] in the Desidustat group and a decrease of 1.13 g/l [95%CI: -3.68, 1.41] in the placebo group, for a between-group difference of 17.52 g/l [95%CI:14.353, 20.681], with the lower limit of 95% CI above 0.

The Product is administrated orally, thus expecting to improve the treatment compliance of patients and to meet the unmet treatment needs in the field of CKD anaemia, including both dialysis and non-dialysis patients. Desidustat Tablets have been approved for marketing in India.

CMS INTERNATIONAL DEVELOPMENT AND MANAGEMENT LIMITED, a wholly-owned subsidiary of the Group, obtained an exclusive license for the Product from Zydus Lifesciences Limited (earlier known as Cadila Healthcare Limited) on 20 January 2020.

Reference:

1. ZhangL, WangF, WangL, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey[J]. Lancet, 2012, 379(9818):815-822. DOI: 10.1016/S0140-6736(12)60033-6

2. Chinese expert consensus on diagnosis and therapy of renal anaemia (the 2014 revised edition), Chinese Journal of Nephrology, 2014;30:712-716

3. Chinese expert consensus on diagnosis and therapy of renal anaemia (the 2018 revised edition), Chinese Journal of Nephrology, 2018, 34(11): 860-866

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever.

Media Contact
Brand: China Medical System Holdings Ltd.
Contact: CMS Investor Relations
Website: https://web.cms.net.cn/en/home/

Source: China Medical System Holdings Ltd.

EM2AI Revolutionising the Dental Industry: New AI Products Promise Transparent Treatment Plans for Patients

SINGAPORE, Apr 23, 2024 – (ACN Newswire) – EM2AI Pte. Ltd., (“EM2AI” or the “Company”) an Artificial Intelligence (AI) dental healthcare company based in Singapore today announced a groundbreaking development poised to reshape the landscape of dental care, with the launch of its pioneering dental AI product. Scheduled to go live later this year, this innovative tool aims to provide dentists and patients with unparalleled transparency and accuracy in treatment planning, marking a significant leap forward for the dental industry.

Mr Ryan San, Chief Executive Officer of EM2AI expressed profound enthusiasm about the forthcoming launch, stating, “Our new dental AI product represents a culmination of years of rigorous research and development, supported by key government agencies such as AI Singapore that have been tasked to promulgate the usage of AI in Singapore. With this revolutionary technology, we are empowering both dentists and patients with the ability to access transparent treatment plans devoid of bias or preference, ensuring full disclosure and transparency in every aspect of dental care.”

Powered by cutting-edge generative AI algorithms, this groundbreaking solution analyses a comprehensive array of patient-specific data, including medical, dental, and social history, demographics, concerns, and investigations. By leveraging this wealth of information, EM2AI is pioneering a transformative approach to formulate optimal dental treatment plans, heralding a new era of precision and integrity in dental healthcare.

EM2AI has developed and successfully deployed the Artificial Intelligence X-Ray Dental Condition Detection and Automated Dental Charting (ADC) systems in all Q & M Dental clinics in Singapore. These are integrated into the Q & M app that is now available to the public for download.

EM2AI is now in the early stages of rolling out the Generative AI Treatment Plan (GATP) in selected outlets for testing with the view for a full rollout in due course. This ground-breaking AI-driven system is designed to support dentists by enhancing the speed and accuracy of diagnosing and creating treatment plans for their patients. The core advantage of GATP lies in its ability to minimise and remove perceived or unperceived biases or preferences that a dentist might hold, thus improving the transparency, reliability, consistency, and quality of dental diagnoses and treatments.

“EM2AI’s integration of AI in dentistry addresses patients’ concern about excessive or insufficient treatment recommendations, fostering an ethical dental approach that patients are actively pursuing. AI Singapore is committed to driving Singapore’s journey as an AI-first nation. We want to continue supporting our local enterprises as they innovate with AI integration in their offerings, striving to elevate consumer experiences and make a positive impact on society,” said Mr Laurence Liew, Director of AI Innovation, AI Singapore.

Furthermore, EM2AI’s model represents a new business paradigm within the dental industry through its Software as a Service (SaaS) offering. The SaaS platform ensures that dental clinics, regardless of their size, can offer state-of-the-art and personalised treatment plans to their patients, fostering a more inclusive and advanced dental care ecosystem. Through continuous updates and improvements, EM2AI’s system promises to evolve alongside advancements in AI and dental medicine, ensuring that dentists are always equipped with the most effective tools to serve their patients.

With this launch, the Company also plans to seek investors and strategic partners, both locally and overseas, for the next phase of the Company’s growth plans.

About EM2AI

EM2AI Pte. Ltd. (“EM2AI”) is a 49%-owned company of Q & M Dental Group (Singapore) Limited (QC7.SI) focusing on developing AI-powered solutions, including a cloud-based Integrated Dental Management System (“EM2Clinic’’) that facilitates patients and clinic management in an efficient way.

For more information, please contact: Waterbrooks Consultants Pte Ltd
Wayne Koo – wayne.koo@waterbrooks.com.sg +65 9338-8166
Derek Yeo – derek@waterbrooks.com.sg +65 9791-4707

Proud Investor Relations partner: https://www.waterbrooks.com.sg/ and https://www.shareinvestorholdings.com/

Avance Clinical Showcases Clinical Excellence at World Orphan Drug Conference in Boston, April 23-25

North Carolina, USA & Adelaide, Australia, Apr 19, 2024 – (ACN Newswire) – Avance Clinical, the award-winning North American and Australian market-leading CRO for biotechs, will attend World Orphan Drug Conference in Boston (April 23-25, 2024) to share their rare diseases drug development expertise with biotechs (booth #730).

Avance Clinical CEO, Yvonne Lungershausen said that Avance Clinical is dedicated to advancing research and ensuring faster access to therapies that can make a significant difference in patients’ lives.

“Avance Clinical has deep therapeutic knowledge of this area, completing over 50 trials in rare and orphan diseases globally in the last five years, including Fragile X Syndrome, Duchenne Muscular Dystrophy, Rett Syndrome and Erythropoietic Protoporphyria,” she said.

Central to the company’s success in this sector is collaboration with disease-specific advocacy groups, patient registries, and tailored recruitment strategies, to enhance patient enrolment and retention.

Lungershausen said, “We have an extensive understanding of the unique challenges in managing small patient populations. Our patient-centric approach places patients at the heart of our operations, ensuring optimal care through the selection of experienced sites and clinics.

“Avance Clinical engages with clients early in the planning process to tailor trial designs to accommodate the unique needs and challenges faced by patients with rare diseases, ultimately improving patient access to critical medicines,” she said.

Avance Clinical is adept at crafting adaptive, patient-focused protocols that adhere to regulatory standards. The company’s innovative approach to study design, combined with over 26 years of experience in delivering FDA and EMA-quality data, positions Avance Clinical as a CRO capable of navigating the complexities of the regulatory landscape efficiently.

Lungershausen describes Avance Clinical as a mid-sized, agile, and responsive CRO with a proven track record of swiftly advancing high-quality clinical programs. “This makes us an ideal CRO partner for rare disease-focussed biotechs,” she said.

“Avance Clinical is focussed on accelerating drug development for its biotech clients, from preclinical stages through to Phase III,” she said.

“This is our GlobalReady program and we have more than 90 biotech clients leveraging this unique, streamlined multi-region process. With a globalized strategy, we ensure efficiency every step of the way,” she said.

“Biotechs are looking for a partner that can seamlessly help transition rapidly with high-quality data that is readily accepted by the FDA and other regulatory agencies. Our in-house global regulatory affairs team assists biotechs to navigate regulatory complexities with confidence and support our clients with FDA, EMA and TGA submissions,” she said.

“In addition, our GlobalReady Site Partnership Network of over 1,250 highly qualified sites across the United States ensures maximum efficiency and effectiveness in our biotech’s clinical trials, particularly in rare and orphan indications,” she said.

New analysis by market research leader Frost & Sullivan shows one of the major challenges for biotechs was finding the right biotech aligned CRO partner.

“More than 60% of US biotechs experience delays seeking the right CRO partner to accelerate their drug development programs,” Lungershausen said. (See report here).

The comprehensive report underscores the increasing biotech preference to collaborate with the right sized CROs that can accommodate the fast-paced nature of biotech demands.

Executive Vice President, North America Operations, John Mann, will attend the conference in Boston alongside Avance’s team of clinical trial experts, including Senior Vice President, Scientific and Regulatory Affairs Kevin Leach and Director of Business Development Clint Henry.

Visit Booth #730 to discuss your upcoming clinical trial, and find out more about the Avance Clinical Advantage, supporting biotechs globally in their clinical development programs.

Book a meeting with the team here

Find out more:

Learn about the GlobalReady model here https://www.avancecro.com/avance-clinical-north-america-operations/
For more information about the benefits of running your next study with Avance Clinical contact us
Visit Booth #730 to discuss your drug development program at the World Orphan Drug Congress in Boston, April 23- 25

Media Contact:
Avance Clinical
media@avancecro.com
Kate Thompson

About Avance Clinical

Avance Clinical is the largest premium full-service Australian and North American CRO delivering quality clinical trials, with globally accepted data, in Australia, New Zealand and the US for international biotechs. The company’s clients are biotechs completing Phase I to Phase III of their drug development program that requires fast, agile, and adaptive solution-oriented clinical research services.

Frost & Sullivan Awards
Avance Clinical, a Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient for the past four years, has been providing CRO services in the region for more than 26 years.

Pre-clinical through to mid to late phase
Avance Clinical offers pre-clinical services with their experienced ClinicReady team right from pre-clinical consultancy through to Phase III clinical services leveraging global reach, supported by significant Australian Government incentive rebates of up to 43.5% and rapid start-up regulatory processes.

With experience across more than 120 indications, the CRO can deliver world-class results and high-quality internationally accepted data for FDA and EMA review.

Technology
Avance Clinical uses state-of-the-art technology and gold standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, TrialHub, Certinia, Salesforce, Zelta and Medrio are just some of the technology partners.

www.avancecro.com

DC Healthcare Rides the Wave of Success with New Openings at Publika and Bukit Indah

KUALA LUMPUR, Apr 18, 2024 – (ACN Newswire) – DC Healthcare Holdings Berhad (“DC Healthcare” or the “Group”), an aesthetic medical services provider specialising in the provision of non-invasive and minimally invasive procedures, is pleased to announce the opening of one Dr. Chong Clinic and one DC Body in KL Publika Shopping Gallery as well as one DC Body Johor Bahru Bukit Indah following the successful launch of multiple Dr. Chong Clinics and DC Body outlets across Malaysia. These additions aim to enhance the availability of DC Healthcare’s top-quality wellness and aesthetic services.

Dr Chong Clinic – KL Publika Shopping Gallery continues the Group’s offering of premier aesthetic services, building on the reputation of excellence that DC Healthcare has established. Meanwhile, DC Body – KL Publika Shopping Gallery and Johor Bahru Bukit Indah represent an innovative leap for DC Healthcare, extending the Group’s offerings into specialised weight management, personalised nutrition counselling and body contouring.

Dr. Chong Tze Sheng, Managing Director of DC Healthcare said, “The positive feedback from our customers from the recent outlets openings of Dr Chong Clinic and DC Body in Ipoh, Johor, Penang and Selangor has inspired us to continue growing. Our new facilities at Publika and Bukit Indah reinforce our commitment to meet the demand for professional wellness and beauty services. We look forward to serving more customers in these new locations.”

He added, “The selection of Publika aligns with the Group’s strategy to integrate into areas that support the lifestyle preferences of our clients. Both new establishments are designed to meet the high standards of care and professionalism expected from DC Healthcare.”

In 2024, DC Healthcare has expanded its reach by opening four Dr. Chong Clinics located in Taman Molek (Johor Bahru), Bandar Seri Botani (Ipoh), Auto City (Pulau Pinang), and Publika (Kuala Lumpur), as well as four DC Body outlets in USJ Taipan (Selangor), Auto City (Pulau Pinang), Publika (Kuala Lumpur), and Bukit Indah (Johor Bahru). With these latest additions, DC Healthcare now operates a total of 17 medical aesthetic clinics and 4 DC Body outlets nationwide, significantly enhancing the accessibility and availability of its premium wellness and aesthetic services to a broader audience.

Managing Director of DC Healthcare, Dr. Chong Tze Sheng

Autonomix Medical Inc. Covered in Benzinga Article Highlighting Innovative Nerve Treatment Technology

NEW YORK, Apr 16, 2024 – (ACN Newswire) – A new article on Autonomix Medical Inc. (NASDAQ: AMIX), featuring the company’s groundbreaking approach to peripheral nervous system (PNS) disorders, has been published by Benzinga. The Benzinga article delves into the critical role of the PNS in human health and highlights how Autonomix Medical is pioneering with its catheter-based microchip sensing array technology.

The article provides a comprehensive look at how Autonomix Medical is redefining treatment protocols for nerve-related disorders. By targeting the root causes associated with the PNS, rather than just managing symptoms, Autonomix Medical’s technology offers a novel solution that combines both detection and ablation of problematic nerves in a single procedure. This approach, likened to a “GPS” for nerve treatment, allows for precise identification and treatment of the nerves involved, enhancing the accuracy and effectiveness of procedures.

In a notable application, the company is focusing its efforts on managing pancreatic cancer pain — a condition notoriously difficult to treat due to its proximity to critical nerves. The technology’s high sensitivity in detecting neural signals—up to 3,000 times greater than existing technologies — promises not only to improve outcomes in pain management but also to significantly reduce the need for opioids, addressing a major public health challenge.

This exposure in Benzinga underscores the potential of Autonomix Medical’s technology to transform the field of electrophysiology and pain management, potentially tapping into a market exceeding $100 billion. As the company progresses with its clinical trials, the successful implementation of its technology could revolutionize treatment approaches for a wide range of diseases, offering hope to millions of patients worldwide.

To read the full article, click here.

More Pancreatic Cancer News:

Candel Therapeutics, Inc. ((Nasdaq: CADL) announced that the FDA has granted Orphan Drug Designation to their advanced biological immunotherapy, CAN-2409, for treating pancreatic cancer, following promising phase 2 clinical trial results that more than doubled median overall survival when added to standard care.
RenovoRx, Inc. (Nasdaq: RNXT) announced an $11.1 million private placement, extending their financial runway into 2026, which will support the continuation and completion of their pivotal Phase III TIGeR-PaC clinical trial for pancreatic cancer. This funding also facilitates the expansion of their Trans-Arterial Micro-Perfusion (TAMP) clinical development pipeline into additional cancer indications.

Note: The details provided in this press release are based on information featured in the Benzinga article and do not constitute forward-looking statements.

For more information, contact:
Plato Data Intelligence
144 E44th St
New York NY 10017
PlatoAiStream.com
Zephyr@platodata.io